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Abstract
Corticotropin-releasing hormone (CRH) receptor type 1 (CRF1) is a member of the receptor
family mediating the effects of CRH, a critical neuromediator of stress-related endocrine,
autonomic, and behavioral responses. The detailed organization and fine localization of CRF1-like
immunoreactivity (CRF1-LI) containing neurons in the rodent have not been described, and is
important to better define the functions of this receptor. Here we characterize in detail the
neuroanatomical distribution of CRF1-immunoreactive (CRF1-ir) neurons in the mouse brain,
using an antiserum directed against the C-terminus of the receptor. We show that CRF1-LI is
abundantly yet selectively expressed, and its localization generally overlaps the target regions of
CRH-expressing projections and the established distribution of CRF1 mRNA, with several
intriguing exceptions. The most intensely CRF1-LI-labeled neurons are found in discrete neuronal
systems, i.e., hypothalamic nuclei (paraventricular, supraoptic, and arcuate), major cholinergic and
monoaminergic cell groups, and specific sensory relay and association thalamic nuclei. Pyramidal
neurons in neocortex and magnocellular cells in basal amygdaloid nucleus are also intensely
CRF1-ir. Finally, intense CRF1-LI is evident in brainstem auditory associated nuclei and several
cranial nerves nuclei, as well as in cerebellar Purkinje cells. In addition to their regional
specificity, CRF1-LI-labeled neurons are characterized by discrete patterns of the intracellular
distribution of the immunoreaction product. While generally membrane associated, CRF1-LI may
be classified as granular, punctate, or homogenous deposits, consistent with differential membrane
localization. The selective distribution and morphological diversity of CRF1-ir neurons suggest
that CRF1 may mediate distinct functions in different regions of the mouse brain.
Indexing terms
CRH; CRF; CRF-R1; rodent; immunocytochemistry; central nervous system
Corticotropin-releasing hormone (CRH), a 41-amino acid neuropeptide, is the primary
hypothalamic factor involved in controlling the synthesis and release of adrenocorticotropic
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hormone (ACTH) from the anterior pituitary (Vale et al., 1981). A large body of evidence
indicates that CRH acts as a physiological mediator of stress-related functions (Aldenhoff et
al., 1983; Ehlers et al., 1983; Siggins et al., 1985; Swanson et al., 1986; Conti and Foote,
1995; Sawchenko et al., 1996; Baram and Hatalski, 1998). CRH has also been demonstrated
to be widely distributed throughout the brain (Swanson et al., 1983; Sawchenko and
Swanson, 1985; Imaki et al., 1991; Sawchenko et al., 1993). In several regions, the peptide
has been shown to have many of the physiological characteristics of a neurotransmitter
(Young et al., 1986; Powers et al., 1987; Valentino and Wehby, 1988; Sawchenko et al.,
1993).
The actions of CRH are mediated via interaction with distinct CRH receptors (Grigoriadis et
al., 1996). Two general members of the CRH receptor family are currently known and
consist of membrane-spanning G-protein-coupled molecules. The first, CRF1 (or CRF-R1),
has been cloned and functionally characterized in a number of species (Chang et al.,1993;
Chen et al., 1993; Perrin et al., 1993; Palchaudhuri et al., 1998). This receptor binds CRH
with high affinity and is positively linked to adenylate cyclase. Rat CRF1 is found in the
pituitary and the central nervous system (CNS) and is the candidate mediator for many of
the neuroendocrine and neuromodulatory effects of CRH (De Souza et al., 1985; Potter et
al., 1994; Chalmers et al., 1995; Baram et al., 1997; Radulovic et al., 1998). The amino acid
sequence of mouse CRF1 is highly similar to that of rat CRF1 (Vita et al., 1993). However,
recently, Radulovic et al. (1998) showed that CRF1 is differently glycosylated in rat and
mouse, as indicated by a higher molecular weight of mouse CRF1 protein. These authors,
using Western blotting, also suggested that the mouse CRF1 may not share the regional brain
distribution of the rat receptor. The second receptor, CRF2, is found in at least three
subtypes in human and rat (CRF2α, CRF2β, and CRF2γ), one of which, CRF2α is found
primarily in the CNS (Lovenberg et al., 1995; Kostich et al., 1998).
The distributions of messenger RNAs (mRNAs) of the two CRH receptors in rat brain have
been demonstrated using in situ hybridization. Thus, Potter et al. (1994) and Chalmers et al.
(1995) described, respectively, the anatomical distribution of CRF1 mRNA and CRF2
mRNA in adult rat brain, demonstrating distinct patterns for each of these receptors. Also,
significant differences in CRH receptor mRNA distribution have been described in different
species (Sanchez et al., 1999). Importantly, the detailed organization and the fine
localization of CRF1 in rodent brain have not been delineated. In addition, mRNA analysis
does not provide information about the intracellular localization of CRF1 to somata versus
processes, or about clustering and synaptic relationships of receptor molecules. Therefore,
the goal of the present study was to utilize immunocytochemical methods to provide a
detailed, single-cell-resolution description of the distribution of CRF1 in the mouse brain.
MATERIALS AND METHODS
Animals
Adult male C57 black mice (2 months old) were used in this study. Because the overall
goals of this series of studies included understanding the possible regulation of CRF1 by its
ligand, CRH, care was taken to utilize mice of similar genetic make-up in all stages of this
effort. Therefore, mice used here were progeny of breeding pairs heterozygous for a null
CRH allele (a generous gift from Dr. J Majzoub). Specifically, transgenic mice in whom an
allele of the CRH gene has been replaced with a neomyocin resistance gene were crossed
back to the C57 background strain for a minimum of 14 generations. Progeny of
heterozygous breeding pairs were genotyped by polymerase chain reaction analysis (Muglia
et al., 1995), and those found to possess both alleles of the CRH gene (wild type) were used
in this study.
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To account for potential variation in CRF1 distribution or abundance deriving from the
specific strain or genetic make-up of these mice, brains from two additional mice from a
separate strain (129/Ola or CD1 strain) were also studied, with essentially indistinguishable
results (not shown). Mice were born and maintained in a federally approved animal facility,
and litter size was culled to six. Mice were kept on a 12-hour light/dark cycle and given free
access to food and water. All experiments were carried out according to NIH guidelines for
the care of experimental animals, with approval by the institutional animal care committee.
Antiserum generation
A polyclonal anti-CRF1 antiserum was generated in goat, against a 20-amino acid peptide
sequence (Santa Cruz Biotechnology, Santa Cruz, CA). The synthetic peptide antigen,
comprising the C-terminus of CRF1 (SIPTSPTRVSFHSIKQSTAL), corresponds to amino
acids 425–444 of human CRF1 and is identical with amino acids 396–415 of mouse and rat
CRF1. This sequence differs by three amino acids from the corresponding portion (412–431)
of mouse CRF2. A search of GenBank and SwissProt data bases revealed no known
sequences (aside from CRH receptors of other species) with significant homology to this
portion of the CRF1 receptor. To characterize the antigen interacting with the antiserum
further, Western blotting was also carried out. To determine whether cross-reactivity with
the CRF2 receptor occurred at the dilution used in this study (as suggested by the
manufacturer), sections of mouse heart, known to express only the CRF2 receptor, were
subjected to immunocytochemistry in parallel with brain sections.
Western blotting
Brains were rapidly dissected from adult mice of two strains that were killed by
decapitation. The hypothalamus and cerebellum were then separated carefully and
homogenized in 50 mM Tris-HCl (pH 7.4, 4°C) containing 150 mM NaCl, 0.25% sodium
dodecyl sulfate (SDS), 0.25% sodium deoxycholate, 1 mM EDTA, 2 µg/ml aprotinin, 2 µg/
ml leupeptin, and 2 µg/ml pepstatin. The crude extracts were centrifuged at 14,000 rpm for
20 minutes at 4°C. The supernatant was collected and centrifuged for 10 minutes. The clear
supernatant fluid (containing soluble proteins and membrane fraction) was then collected for
the following analysis. Protein concentration was determined using BCA Protein Assay
(Pierce, Rockford, IL), and 50-µg protein aliquots were size-fractionated on 4–12% Tris-
glycine gel (Novex, Carlsbad, CA) at 120 V for 2.5 hours.
After electrophoresis, proteins were transferred to Hybond-ECL membrane (Amersham,
Arlington Heights, IL). Nonfat milk (6%) in Tris-buffered saline (25 mM Tris, 0.15 M NaCl,
pH 7.2) containing 0.05% Tween-20 (TBS-T) was used for blocking and for dilution of
primary and secondary antibodies. The membrane was blocked overnight at 4°C and then
incubated for 2 hours at room temperature with the anti-CRF1 antiserum (1:500). After
several washes with TBS-T, the membrane was incubated in horseradish peroxidase-
conjugated anti-goat IgG (1:10,000, Jackson ImmunoResearch, West Grove, PA) for 1.5
hours at room temperature. Following rinsing with TBS-T, bound antibody was detected
using the ECL detection system (Amersham). For control, the primary antiserum was
preadsorbed overnight at 4°C with purified CRF1 blocking peptide (100 µg/ml; Santa Cruz
Biotechnology).
Immunocytochemistry
Care was taken to harvest tissue under relatively stress-free conditions (Yan et al., 1998a,b).
Briefly, mice (n = 4) were undisturbed for at least 24 hours prior to experiments and then
deeply anesthetized with sodium pentobarbital (100 mg/kg intraperitoneally) within 45
seconds of initial handling. Mice were then removed to the laboratory and perfused via the
ascending aorta with 0.9% saline solution followed by freshly prepared 4%
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paraformaldehyde in 0.1 M sodium phosphate buffer (PB, pH 7.4, 4°C). Brains were
dissected from the skull, postfixed for 4 hours, and immersed in 15%, followed by 25%
sucrose for cryoprotection. Brains were blocked in the coronal or sagittal planes and
sectioned at 20-µm thickness using a cryostat. In each plane, one in eight matched sections
(one in four for the hypothalamic region) were subjected to immunocytochemistry, and an
adjacent series of sections was stained with cresyl violet.
For CRF1-LI immunocytochemistry, free-floating sections were collected into tissue-culture
wells in 0.1 M PB and subjected to standard avidin-biotin complex (ABC) methods (Chen et
al., 1998a; Yan et al., 1998a,b). Briefly, after several washes with 0.01 M phosphate-
buffered saline (PBS) containing 0.3% Triton X-100 (pH 7.4, PBS-T), sections were treated
for 30 minutes in 0.3% H2O2 in PBS, followed by blockade of nonspecific sites with 2%
normal rabbit serum in PBS for 30 minutes. After a 10-minute rinse in PBS, sections were
incubated for 48 hours at 4°C with anti-CRF1 (1:5,000) in PBS containing 1% bovine serum
albumin and 2% normal rabbit serum and washed 3 times in PBS-T, 5 minutes each.
Subsequently, sections were incubated in biotinylated rabbit-anti-goat IgG (1: 200, Vector,
Burlingame, CA) in PBS for 1 hour at room temperature. After washing in PBS-T (3 × 5
minutes), sections were incubated in ABC solution (1:100; Vector) for 2 hours at room
temperature. Sections were then rinsed again in PBS-T (3 × 5 minutes). The reaction product
was visualized by incubating sections for 8–10 minutes in 0.04% 3,3′-diaminobenzidine
(DAB) containing 0.01% H2O2 with or without 0.5% nickel chloride.
Several approaches were used to address the specificity of the immunostaining obtained
with anti-CRF1. In addition to the Western blotting described above, the specificity of the
primary antiserum was also tested by substituting normal goat IgG (1:1,000–5,000; Santa
Cruz Biotechnology) for the primary antiserum and by preadsorbing the antiserum overnight
with purified CRF1 blocking peptide (100 µg/ml). The specificity of the second antibody
was tested by omitting the primary antiserum during the first incubation. As indicated above,
cross-reactivity with CRF2 was tested by using the antiserum for staining mouse heart tissue,
known to express CRF2 only.
Regional and laminar distribution patterns of CRF1-LI were determined by comparison of
immunocytochemical sections with adjacent cresyl-violet stained sections and by evaluation
of methyl green-counterstained sections. Published nomenclature was used to identify
cytoarchitectonic areas in the cortex (Dolorfo and Amaral, 1998), amygdala (Pitkänen et al.,
1997), hypothalamic paraventricular nucleus (Swanson and Kuypers, 1980; Swanson et al.,
1983), and other regions (Sidman et al., 1971; Paxinos and Watson, 1982).
Density and intensity of CRF1-LI-labeled neurons
The relative density of CRF1-ir neurons was assessed with a square lattice system (Chen et
al., 1998b) over the entire area examined, using light microscopy at ×400 magnification.
Density was expressed as the percentage of positive cells related to total cell number in the
region of interest or in a 0.01-mm2 real area, based on the average value from three fields
per section. Generally, three to five sections were counted in every mouse for evaluating
CRF1-ir neuronal density in each brain structure or nucleus, and the percentage of CRF1-ir
neurons was calculated by dividing the total number of CRF1-ir neurons by the sum of
Nissl-stained cells. The intensity of CRF1-LI labeling was scored as weak (+), moderate (+
+), intense (+++), or strongly intense (++++).
RESULTS
The specificity of the anti-CRF1 antiserum was assessed by immunoblotting mouse
hypothalamus and cerebellum homogenates (Fig. 1). As shown in lanes 1 and 2, the
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antiserum recognized an approximately 80-kDa protein, in good agreement with the
molecular weight of mouse brain CRF1 protein (Radulovic et al., 1998). Preadsorption of the
primary antiserum with a blocking peptide consisting of the immunogenic epitope (100 µg/
ml) completely abolished the CRF1 band (Fig. 1, lanes 3 and 4). The specificity of CRF1
immunoreactivity was also indicated by the absence of labeled neurons or fibers in brain
sections that were stained using antiserum pretreated with the antigenic peptide (Fig. 2D). In
addition, no staining was observed on the sections when normal goat IgG was substituted for
the CRF1-directed serum or in the absence of the primary antiserum (not shown). Finally,
cross-reactivity with the CRF2 receptor was excluded by the absence of any signal in mouse
heart specimens run in parallel to immunopositive brain sections (not shown).
CRF1-LI neurons were widely but selectively distributed throughout the mouse brain. In
addition, the intensity of CRF1 reaction product in positive neurons differed in a neuron- and
region-specific manner. In general (but not always; see Fig. 2C), CRF1-LI in most involved
brain regions showed a pattern typical of membrane localization and was further
characterized as either granular (associated with intensely labeled neurons) or finely
punctate (generally present in moderately or weakly labeled cells). A third pattern, a
homogenous deposit associated with the plasma membrane, was found in several regions
(Fig. 2A–C). Notably, intensity of the CRF1 immunoreaction product was maximal in
neocortical pyramidal cells, Purkinje cells, and most positive neurons in the thalamus,
hypothalamus, and brainstem nuclei.
The distribution of CRF1-LI neurons in the four mouse brains studied in detail was
essentially identical, with relatively modest variation in labeling intensity among animals.
The following is a description of the distribution of CRF1-LI neurons by region.
Telencephalon
Table 1 outlines the distribution of CRF1-LI in the telencephalon.
Olfactory bulb and tubercle—In the olfactory bulb (Fig. 3A), many periglomerular cells
were intensely CRF1-LI labeled and thus outlined the glomeruli that were unstained. In
addition, a few large, multipolar, intensely labeled neurons were observed just beneath the
glomerular layer. Mitral cells were moderately or weakly immunoreactive, and some weakly
labeled neurons were also present in the external and internal plexiform layers. In addition,
some immunoreactive puncta were observed in the internal plexiform layer and, rarely, in
the external plexiform layer. The granular layer contained numerous labeled puncta and
scattered CRF1-LI neurons. The distribution pattern of CRF1-LI in the accessory olfactory
bulb resembled that found in the main bulb; conversely, most neurons in the anterior
olfactory nucleus were CRF1-ir. Within the olfactory tubercle (Fig. 3B), moderately CRF1-
LI-labeled neurons were prominent in the pyramidal layer. Scattered large, multipolar,
intensely labeled neurons and some medium-size, weakly labeled cells were seen in the
polymorphic layer, but none in the plexiform layer. The islands of Calleja contained
moderately labeled CRF1 granular reaction products, whereas neurons in the taenia tecta
were moderately immunoreactive.
Cerebral cortex—Neocortical areas contained a large number of CRF1-LI neurons, the
intensity of which differed substantially across regions. The most intensely labeled neurons
occurred in the cingulate cortex and in the somatosensory area of the frontoparietal cortex,
followed by the motor area of frontoparietal cortex. CRF1-LI neurons in the association
areas of the striate and temporal cortices were characterized by moderately intense reaction
product. The laminar distribution of CRF1-LI-labeled neurons was striking: in the cingulate,
frontoparietal, and most other neocortical regions, whereas immunopositive neurons were
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distributed throughout layers II–VI, maximal intensity of the reaction product was found in
layer V, most notably in the frontoparietal cortex motor area (Fig. 3C). In addition, rare
CRF1-LI neurons were observed in layer I and in subcortical white matter. Within piriform
cortex, moderately labeled CRF1-ir neurons were common in both the pyramidal (II) and
polymorphic (III) layers, intermingled with a smaller population of intensely labeled cells
(Fig. 3D). In the entorhinal cortex, many moderately labeled neurons were distributed in
layers II and III, accompanied by a scattered population of large, multipolar, intensely
labeled neurons. CRF1-LI neurons in layers V–VI were moderately labeled (Fig. 3E).
Perirhinal cortex contained CRF1-LI-labeled neurons uniformly throughout layers II and III.
Hippocampal formation—Within the hippocampus, CRF1-LI-containing neurons were
most prominent in the pyramidal cell layer: the CA1 pyramidal cell layer was rich in
moderately labeled puncta and contained several intensely labeled large neurons. CA2 was
distinguished by intense or moderate labeling of virtually all pyramidal neurons. In CA3,
maximal intensity of CRF1-ir was found in CA3a, with a gradual decline over CA3b and a
fainter signal over CA3c. Outside the pyramidal layer, only occasional medium-sized,
multipolar or fusiform CRF1-ir neurons were scattered in the strata oriens, lacunosum-
moleculare, and radiatum (Fig. 4A,B). Within the dentate gyrus, granule cell somata were
outlined by a fine mesh of weakly stained puncta, and occasional strongly labeled basket-
like neurons were visible. Large, polymorphic, intensely labeled neurons were present in the
hilus, whereas little CRF1-LI was observed in the molecular layer (Fig. 4A,C). Within the
subiculum, many pyramidal neurons were intensely labeled (Fig. 4D).
Amygdala—Large, intensely labeled neurons were widely distributed throughout the basal
nucleus (Fig. 5A,B). The staining pattern of the accessory basal nucleus consisted of weakly
labeled medium-sized neurons, and this pattern was shared by the medial nucleus: in both
nuclei, only a portion of the cell surface typically showed CRF1-LI (Fig. 5C). Most neurons
were immunoreactive in the anterior cortical nucleus, with a similar pattern but lower
intensity than in the medial nucleus. In the central nucleus (ACe), weak to moderate CRF1-
LI labeling was found in both lateral and medial divisions, but with a different staining
pattern: whereas immunoreactivity in the lateral division consisted of punctate deposits, the
medial division pattern consisted of crescent-shaped contours (similar to the pattern found in
medial and accessory basal nuclei; Fig. 5D). Finally, weakly labeled neurons were present in
the lateral nucleus. Within the bed nucleus of stria terminalis (considered a part of the
“extended amygdala”), moderately labeled puncta were abundant in both medial and lateral
areas (not shown).
Basal forebrain—Most lateral septal nucleus neurons showed intense CRF1-LI.
Interestingly, each subnucleus demonstrated a distinct immunoreactivity pattern (Fig. 6A–
C): the dorsal region contained many medium-size neurons with granular CRF1-LI deposits
(Fig. 6B), whereas the intermediate region also contained (medially) cells with a fine
punctate CRF1-LI pattern and short processes. A third pattern, consisting of large granular
deposits without a distinct neuronal contour, was observed in the ventral region of this septal
nucleus (Fig. 6C). The medial septum contained many large, intensely or moderately labeled
neurons, whereas multipolar, intense CRF1-LI-labeled magocellular neurons were abundant
in both the horizontal and vertical limbs of the diagonal band of Broca (Fig. 6D).
Basal ganglia—Most CRF1-LI neurons in the striatum (caudate-putamen) were weakly
labeled and were accompanied by scattered medium-sized, intensely labeled cells (Fig. 6E).
A similar but more intense labeling pattern was evident in the nucleus accumbens (Fig. 6F).
The fundus striati and ventral endopiriform nucleus were characterized by abundant,
moderately CRF1-LI neurons. A population of larger, multipolar or fusiform process-
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possessing neurons was encountered in the globus pallidus and the ventral pallidum (Fig.
6F), whereas the entopeduncular nucleus contained moderate numbers of intensely CRF1-LI
cells.
Diencephalon
Table 2 outlines the distribution of CRF1-LI neurons in the diencephalon.
Habenula—Small neurons in medial habenula were intensely CRF1-LI labeled, whereas
lateral habenula showed numerous moderately CRF1-LI neurons and scattered intensely
labeled cells (Fig. 7A).
Thalamus—The anterior nuclear group demonstrated numerous CRF1-LI strongly labeled
neurons (in the anterodorsal and anteromedial nuclei) and moderately labeled ones
(anteroventral nucleus) (Fig. 7A). Many neurons with intensely labeled somata and short
processes were found in the mediodorsal nucleus. In the lateral nuclear group, the dorsal and
posterior nuclei contained multipolar or triangular intensely CRF1-LI neurons possessing
short processes. In the ventral group, intensely labeled neurons were abundant in the lateral,
posterolateral, and posteromedial nuclei, as well as in the midline nuclear group (paratenial,
paraventricular, and reuniens nuclei) and in the intralaminar nuclear group. In the thalamic
reticular nucleus, only weak or moderate CRF1-LI was found (Fig. 7B).
Hypothalamus—Within hypothalamus, most CRF1-LI labeling of neurons was intense,
especially in the supraoptic, paraventricular (PVN), ventromedial (VMH), and arcuate nuclei
(Fig. 8A–F). The medial preoptic area contained numerous highly CRF1-LI neurons,
reminiscent of those of the amygdaloid medial nucleus, whereas the lateral preoptic nucleus
contained triangular or fusiform, moderately labeled cells bearing several short processes.
The suprachiasmatic nucleus was characterized by densely immunoreactive neuropil,
whereas the retrochias-matic area contained a few weakly CRF1-LI-positive neurons in
conjunction with scattered intensely CRF1-LI-positive puncta. Neurons in the supraoptic
nucleus were more strongly immunolabeled than those in the suprachiasmatic nucleus (Fig.
8D). Parvocellular neurons of the PVN demonstrated exceptionally strong CRF1-LI; in
contrast, few positive neurons were present in the magnocellular divisions (Fig. 8A–C). In
the VMH, neurons were intensely labeled ventrolaterally and moderately labeled in the
dorsomedial part, in a granular pattern. Intensity of CRF1-ir in the arcuate nucleus was
higher than that observed in the VMH (Fig. 8E,F). Staining intensity of CRF1-LI in neurons
of the posterior lateral hypothalamic area was mostly weak or moderate. Interestingly,
several subependymal neurons in the median eminence showed CRF1-LI (Fig. 8E).
Subthalamus and geniculate bodies—Subthalamic neurons showed CRF1-LI, as did
most zona incerta cells (Fig. 7C). In the lateral geniculate body, neurons were generally
intensely labeled dorsally and moderately or weakly labeled in the ventral parts, whereas
both parts of the medial geniculate body contained intensely immuno-reactive neurons.
Mesencephalon
Table 3 outlines the distribution of CRF1-LI-expressing neurons in the mesencephalon. A
large number of CRF1-LI-labeled neurons was observed in the tectum. Within layers II–VII
of the superior colliculus, these neurons were moderately or weakly immunoreactive,
accompanied by a few large, multipolar, deeply labeled cells in the lateral part of layer VI
and occasionally in layer VII (Fig. 9A). The most striking feature of the inferior colliculus
was large, multipolar or triangular, strongly CRF1-LI neurons in both the cortical and central
nuclei, where most medium-sized neurons were moderately stained (Fig. 9B). Comparison
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of the dorsal and lateral inferior colliculus cortex revealed a few CRF1-LI neurons in the
latter.
Within tegmental nuclei, labeling intensity was maximal in the ventral (Fig. 9C), moderate
in the laterodorsal, and weak in the dorsal nucleus (Fig. 9C,G). Neurons in the pedunculo-
pontine-tegmental and reticulotegmental nuclei were strongly labeled. In red nucleus, most
large neurons with short processes were intensely labeled (Fig. 9D). The substantia nigra
pars reticulata was characterized by large, multipolar, neurons with intense CRF1-LI,
whereas the pars compacta contained medium, moderately to intensely labeled cells (Fig.
9E). Similarly, process-bearing neurons in the interpeduncular nucleus were moderately or
intensely labeled. The dorsal raphe nucleus was rich in highly labeled neurons, whereas only
modest numbers of intensely stained neurons were observed in the median raphe (Fig. 9G).
Both the accessory (Edinger-Westphal) and principal oculomotor nuclei contained moderate
or intense CRF1-LI (Fig. 9F). Neurons with short processes in the Darkschewitsch nucleus
were moderately labeled. The mesencephalic nucleus of the trigeminal nerve showed intense
CRF-LI in a granular pattern (see Fig. 11A). In addition, many medium-sized, moderately
labeled neurons were present in the central gray, particularly dorsally.
Pons and medulla
Pontine and medullary raphe nuclei shared the staining pattern of their mesencephalic
counterparts. Within the reticular formation, large, multipolar, intense CRF1-LI neurons
were abundant in the pontine and gigantocellular reticular nuclei, whereas only scattered
positive neurons resided in the intermediate and lateral nuclei. The locus coeruleus was rich
in multipolar, intensely CRF1-LI-labeled neurons (see Fig. 11A). Dorsal parabrachial nuclei
were more intensely stained than ventral ones (see Fig. 11B). Large, multipolar neurons in
superior olive and nuclei of lateral lemniscus were also intensely stained.
Within trigeminal nerve nuclei, large, multipolar neurons in the motor, principal sensory,
and spinal subnuclei showed intense CRF1-LI. In addition, numerous moderately labeled
small and medium cells were found in both principal sensory and spinal nuclei (Fig. 10A).
The facial nucleus was rich in large, multipolar CRF1-LI neurons (Fig. 10B), whereas the
vestibular nuclei (medial, lateral, and superior) contained numerous moderately or in-tensely
labeled cells (Fig. 10C). In the cochlear complex, the ventral nucleus had more intense
CRF1-LI than the dorsal nucleus, the latter containing rare highly labeled neurons and some
moderately immunoreactive neurons (Fig. 11C). Some neurons in vagal, ambiguous, and
hypoglossal nuclei showed strong CRF1-LI (Fig. 10D,E). Weak-to-moderate CRF1-LI
labeling occurred in medial and lateral divisions of the solitary tract nucleus (Fig. 10F).
Medium-sized, highly labeled CRF1-LI neurons were observed in the medial nucleus of the
trapezoid body, in contrast to the occasional, intensely labeled cells of the lateral nucleus
(Fig. 11D,E). In the inferior olive, medium-sized CRF1-LI-stained neurons were found (Fig.
11F).
Cerebellum
Purkinje cells showed intense CRF1-LI, in a granular pattern (Figs. 2A, 11G), whereas the
granular layer contained only scattered intensely labeled neurons accompanied by abundant
weakly labeled puncta. Large, multipolar neurons in the deep cerebellar nuclei were
intensely stained, whereas the cerebellar white matter was devoid of CRF1-LI.
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DISCUSSION
The current immunocytochemical study describes the distribution of CRF1-LI throughout
the mouse brain. The results indicate that 1) CRF1-LI is generally localized to the cell
membrane and is further characterized as granular, punctate, or homogenous deposits; 2)
CRF1-LI-labeled neurons are morphologically heterogeneous both within and among brain
structures; 3) CRF1-LI is widely and selectively distributed in discrete regions of the mouse
brain, in a pattern that—with notable exceptions—generally conforms to that of CRF1
mRNA; and 4) a gradient of CRF1-LI labeling intensity exists, with the highest found in
certain hypothalamic nuclei, neocortex, septum, basal amygdala, thalamus, select brain stem
regions, and cerebellar Purkinje cells.
CRF1 immunoreaction product was generally localized to the cell membrane. This result is
consistent with evidence indicating that this receptor is a G-protein-coupled, membrane-
bound protein (Chang et al., 1993; Perrin et al., 1993; Castro et al., 1996). Of the several
patterns of CRF1-LI observed in this study (Fig. 2A–C), some may signify receptor
clustering (granular and punctate deposits). In addition, the spectrum of cellular distribution
patterns of CRF1-LI was remarkable, both within a given nucleus as well as among regions.
Most commonly, punctate or granular CRF1-LI outlined a neuronal profile consisting of the
soma with or without dendritic processes. In some cases, CRF1-LI outlined only part of the
cell surface, suggesting somatic innervation, perhaps by a spatially discrete bundle of axons
(e.g., the climbing fiber innervation of cerebellar molecular layer neurons). Interestingly,
numerous CRF1-LI-labeled puncta were observed in certain regions such as the granular
layers of the olfactory bulb and cerebellum, suggesting a presynaptic location of CRF1.
Thus, the findings of this study are consistent with a potential for not only the post- but also
presynaptic location of CRF1. However, electron microscopic (EM) studies are required to
demonstrate the presence of presynaptic CRF1 definitely.
In general, neurons with CRF1-LI were observed in target regions of CRH-expressing local
circuit and projection neurons. An eloquent example of this notion was evident in the
amygdala. In the ACe, CRH-containing terminals are abundant and have been shown to
arise from cell bodies located in the lateral hypothalamus and dorsal raphe, as well as from
intrinsic CRH neurons in the ACe (Swanson et al., 1983; Uryu et al., 1992). In the present
study, we observed that essentially all ACe neurons were CRF1-LI positive. This indicates
that in the ACe, CRF1-ir neurons may be innervated by CRH-expressing cells originating
both within and outside the amygdala. Interestingly, the density and intensity of CRF1-
immunoreaction product in the ACe were high. In contrast, CRF1 mRNA expression in the
ACe has been found to be modest (Potter et al., 1994; Chalmers et al., 1995; Avishai-Eliner
et al., 1996). Thus, it may be suggested that the CRF1-LI in the ACe may originate in the
somata of other nuclei (e.g., lateral amygdala; Pitkänen et al., 1997) and transported to ACe.
An additional, intriguing possibility is that the ACe may contain novel, as yet
uncharacterized, ligand for this receptor (e.g., Weninger et al., 1999). Whereas levels of
CRF1-LI and mRNA are somewhat discordant in the ACe, the results of the current study—
showing intense labeling of magnocellular neurons in basal nucleus—are in accordance with
levels of CRF1 mRNA expression and CRH receptor binding in this nucleus (De Souza,
1987; Potter et al., 1994; Chalmers et al., 1995; Avishai-Eliner et al., 1996).
CRF1-LI was localized to regions receiving CRH-containing projections from the amygdala.
Indeed, the amygdala is considered an origin of major CRH-containing pathways, emanating
from the ACe, the major output nucleus for amygdaloid projections to the brainstem and
hypothalamus (Swanson et al., 1983; Sakanaka et al., 1986; Gray and Bingaman, 1996;
Pitkänen et al., 1997). CRH neurons in ACe have been shown to project to the bed nucleus
of the stria terminalis (BNST), lateral hypothalamus, midbrain central gray, parabrachial
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nucleus, mesencephalic nucleus of the trigeminal nerve, mesencephalic reticular formation,
solitary tract nucleus, and vagal nucleus (Veening et al., 1984; Sakanaka et al., 1986; Moga
et al., 1989). In view of the widespread CRH projections from the ACe, it is not surprising
that abundant CRF1-LI-expressing neurons are observed in the current study. Indeed, the
distribution of CRF1-LI-labeled neurons demonstrated in this study highly overlaps that of
target regions of CRH-expressing projections from the ACe. An additional CRH-expressing
group of projection neurons originates in the amygdaloid corticomedial nucleus, innervating
the VMH (Sakanaka et al., 1986). Accordingly, the current study demonstrated numerous
CRF1-LI-labeled neurons in VMH.
CRF1-LI-positive neurons were abundant in most cholinergic nuclei of the basal forebrain,
including the septum and the diagonal band of Broca. Interestingly, we found high levels of
CRF1-LI in both the lateral and medial septum, whereas reports on the distribution of CRF1
mRNA have suggested a preferential localization to the medial septum (Chalmers et al.,
1995). In addition, within the lateral septum, regional differences were evident in the
cellular pattern of CRF1-ir, implying regional specificity in the localization and perhaps
physiological functions of this receptor. Thus, the demonstration of CRF1-LI-positive
neurons in cholinergic nuclei afferent to the hippocampal formation may suggest that the
receptor participates in modulation of cholinergic input to the hippocampus.
The current study demonstrated a rich array of CRF1-LI-expressing neurons in the
hippocampal formation. CRH has been shown to influence directly synaptic function in
hippocampal CA1 (Aldenhoff et al., 1983; Smith and Dudek, 1994) and CA3 (Hollrigel et
al., 1998) and to excite hippocampal neurons both in vivo (Baram et al., 1997) and in vitro
(Aldenhoff et al., 1983; Smith and Dudek, 1994; Hollrigel et al., 1998). These effects may
be important in modulating learning and memory processes (Liang and Lee, 1988; Lee et al.,
1993; Behan et al., 1995). Furthermore, recent evidence indicates that at least some of these
direct effects of CRH on hippocampal neurons are mediated by CRF1 (Baram et al., 1997).
In the absence of CRH-containing afferent projections to the hippocampus, the endogenous
ligand for CRF1—shown here to reside primarily on pyramidal layer neurons—is likely to
be CRH found in local hippocampal interneurons, as described by Swanson et al. (1983) and
Sakanaka et al. (1987). Recently most of these neurons have been found to be basket and
chandelier cells, synapsing on soma and axon initial segment of pyramidal neurons,
respectively (Yan et al., 1998b). Thus, local CRH-expressing interneurons are the likely
source of ligand activating the abundant CRF1-LI on hippocampal pyramidal layer neurons.
This study documented a particularly striking density and intensity of CRF1
immunoreactivity in CA3 pyramidal neurons. In this context, it is interesting to note that the
excitatory and particularly the excitotoxic effects of CRH are maximal on CA3 hippocampal
neurons (Baram and Ribak, 1995; Ribak and Baram, 1996).
In the hypothalamus, the current study demonstrated an abundant population of generally
intense CRF1-LI labeling of neurons in the PVN, VMH, and supraoptic and arcuate nuclei.
While a small proportion (about 24%; 96 of 398) of PVN magnocellular neurons showed
faint CRF1-LI, parvocellular neurons were very intensely labeled. Of these, most were
concentrated in the anterior, medial, and lateral parts of the parvocellular division (Swanson
and Kuypers, 1980; Swanson et al., 1983). Previous studies have demonstrated that CRH-
expressing parvocellular neurons of the dorsomedial division of PVN give rise to the
pathway terminating in the external zone of the median eminence (Swanson et al., 1987;
reviewed in Sawchenko and Swanson, 1990) that controls the release of ACTH from the
pituitary. These CRH neurons thus participate in the control of ACTH release from the
anterior pituitary, a key neuroendocrine component of the response to stress. In addition to
this stress axis-related role, subpopulations of PVN CRH neurons, such as those residing in
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the medial and lateral parvocellular regions, project to autonomic cell groups in the
brainstem and spinal cord (Sawchenko, 1987). The current study documents the presence of
CRF1-LI in PVN regions containing both neuroendocrine and autonomic-projecting cells.
These receptors may thus be positioned to modulate both the neuroendocrine and autonomic
functions of CRH.
The current study demonstrates a striking abundance of CRF1-LI in the PVN. This may be
contrasted with previous in situ hybridization studies, showing unexpectedly little CRF1
mRNA expression in the PVN of unstressed rats (Potter et al., 1994; Chalmers et al., 1995;
Avishai-Eliner et al., 1996). However, CRF1 mRNA levels were highly increased by
stressful manipulations (Luo et al., 1994; Rivest et al., 1995; Imaki et al., 1996; Hatalski et
al., 1998), as well as by intracere-broventricular administration of CRH. The current study
demonstrated CRF1-LI in parvocellular neurons from hypothalami of animals obtained
under relatively stress-free circumstances (see Materials and Methods). This indicates that
high CRF1 protein levels may exist concurrent with modest steady-state CRF1 mRNA
levels. This is consistent both with a long half-life of CRF1 and with regulation of receptor
levels at the protein level. Because receptor binding studies have generally demonstrated
modest levels of CRH binding in the PVN (De Souza and Kuhar, 1986), our data may
suggest increased sensitivity of the immunocytochemical approach. In agreement with our
results, Radulovic et al. (1998) recently reported the presence of CRF1-ir neurons in PVN of
both rat and mouse.
It should be noted that it is unlikely that the CRF1-LI observed in this study was a result of
cross-reactivity with CRF2. Substantial homology exists between CRF1 and CRF2 proteins,
and the immunogenic epitope used to generate the antiserum used here shares 17 of 20
amino acids with the C-terminus of CRF2. However, Western blotting at high antiserum
concentration of mouse brain of several strains revealed a single band. In addition, the
overall distribution of CRF1-ir in the current study matched that reported for CRF1 binding
and mRNA, and not that of CRF2. Finally, using the antiserum on mouse heart, known to
express CRF2 but not CRF1, no immunoreactivity was evident, again strongly suggesting
that the antiserum does not recognize CRF2.
In the present study, neurons strongly labeled for CRF1-LI were also evident in the
supraoptic nucleus. In view of the association of such neurons with CRH-expressing cells in
PVN (vide supra), it is notable that a subset of supraoptic nucleus neurons have been shown
to synthesize CRH (Kawata, 1983). CRF1-LI was abundant in both the dorsomedial and
ventromedial VMH. At the mRNA level, CRF1 expression in the VMH has been found to be
low compared with that of CRF2 in both adult and immature animals (Chalmers et al., 1995;
Eghbal-Ahmadi et al., 1998). The VMH functions to regulate food intake and energy
balance. In addition, it is involved with integrating inputs from the HPA-axis, circadian
rhythm, and sensory relay centers (Lovenberg et al., 1995; Eghbal-Ahmadi et al., 1999).
However, the relative roles of CRF1 and CRF2 in mediating the effects of CRH and similar
ligands in the VMH are not fully understood. The relatively high levels of VMH CRF1-LI
found in this study suggest that this receptor may participate in mediating some of the
effects of CRH (and related ligands) in this region.
CRF1-LI was abundant in monoaminergic cell groups such as the locus coeruleus, raphe,
ventral tegmentum, and substantia nigra. Of these, the locus coeruleus has been shown to
contain CRH-expressing neurons and fibers. A number of studies have suggested that CRH
may function as a neurotransmitter in this region, involved with central integration of
autonomic, behavioral, and anxiogenic effects of stressful stimuli (Valentino et al., 1992;
Lehnert et al., 1998). For example, CRH injected into the rodent locus coeruleus produces
an anxiogenic response (Owens and Nemeroff, 1993). In this regard, the present study
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provides an anatomical basis for the involvement of the locus ceruleus CRF1 in mediating
anxiety-related effects of CRH.
CRF1-LI was abundant in cerebellar circuits. CRH has been localized to cerebellar mossy
fiber projections originating in vestibular-related brainstem nuclei (Cha and Foote, 1988;
Cummings et al., 1994) and to the climbing fibers and their origin, the inferior olive (Young
et al., 1986; Cummings et al., 1994; Chang et al., 1996). In accordance with the functional
role of CRH as a cerebellar neurotransmitter, previous studies have demonstrated the
expression of CRF1 and CRF2 mRNAs in the molecular and granular layers, sites of
termination of climbing and mossy fibers, respectively (Potter et al., 1994; Chalmers et al.,
1995). In the present study, almost all Purkinje cells showed intense CRF1-LI, whereas these
levels were generally low in both molecular and granular layers. Thus, whereas the current
immunocytochemical data correlate with mRNA distribution in Purkinje cells (Chalmers et
al., 1995; King et al., 1997), the current study shows low CRF1-LI levels in the granular
layer, considered rich in CRF1 mRNA. This apparent discrepancy may be due to the
synthesis of CRF1 within cell bodies located in the granular layer and transport of the
protein away from the soma, located in the granular layer, resulting in low signal intensity in
this layer (Table 3).
The current study focused on CRF1 detection in the mouse brain; the distribution may differ
from that in rat. Thus, Radulovic et al. (1998) reported significant, although mainly
quantitative, species differences in the distribution of the receptor between the rat and
mouse. Compared with the rat, the mouse was found to express less CRF1 protein in the
neocortex and basal amygdala and significantly larger amounts of CRF1 protein in several
subcortical regions including the substantia nigra, central gray, red and Darkschewitsch
nuclei, and pontine reticular nuclei.
In summary, the present immunocytochemical study reveals that the CRF1-LI is widely yet
selectively expressed in the mouse brain and that its localization generally overlaps target
regions of CRH projections. In addition, CRF1-LI distribution is generally congruent with
previously published data on CRF1 mRNA expression. However, discrepancies do exist in
several regions including the central amygdaloid nucleus, septum, locus coeruleus, certain
hypothalamic nuclei, and the cerebellar granular layer. These, as discussed above, may be
due to differential regulation of receptor transcription and protein, to protein transport, to the
cellular detail afforded by the current study, or to the presence of as yet undiscovered or
cross-reacting ligands and receptors, respectively.
Abbreviations
3 principal oculomotor nucleus
3V third ventricle
7 facial nucleus
10 dorsal motor nucleus of vagus
12 hypoglossal nucleus
AB accessory basal amygdaloid nucleus
aca anterior commisure, anterior part
Acb accumbens nucleus
ACe central amygdaloid nucleus
AD anterodorsal thalamic nucleus
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AHy anterior hypothalamic area
Amb ambiguous nucleus
ap anterior parvocellular part, paraventricular hypothalamic nucleus
Arc arcuate hypothalamic nucleus
AV anteroventral thalamic nucleus
Bmc basal amygdaloid nucleus, magnocellular division
CA1–3 cornu ammonis, hippocampus
cc corpus callosum
CC central canal
CEl central amygdaloid nucleus, lateral division
CEm central amygdaloid nucleus, medial division
CL centrolateral thalamic nucleus
COa anterior cortical amygdaloid nucleus
d dorsal nucleus, inferior olive
DCo dorsal cochlear nucleus
Dk Darkschewitsch nucleus
DPB dorsal parabrachial nucleus
DR dorsal raphe nucleus
DTg dorsal tegmental nucleus
ec external capsule
En endopiriform nucleus
EPl external plexiform layer of olfactory bulb
EW accessory oculomotor nucleus
FStr fundus striate
Gl glomeruli
Grc granular layer of cerebellum
GrCo granular layer of cochlear nucleus
GrDG granular layer of dentate gyrus
Hi hilus of dentate gyrus
ICj islands of Calleja
icp inferior cerebellar peduncle
Igr internal granular layer of olfactory bulb
IO inferior olive
IPl internal plexiform layer of olfactory bulb
LC locus coeruleus
LDTg laterodorsal tegmental nucleus
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lfp longitudinal fasiculus of pons
LH lateral hypothalamic area
Ll lateral amygdaloid nucleus, lateral division
Lm lateral amygdaloid nucleus, medial division
LMol stratum lacunosum-moleculare of hippocampus
lp lateral parvocellular part, paraventricular hypothalamic nucleus
LRt lateral reticular nucleus
LRtS5 lateral reticular nucleus, subtrigeminal part
LSD lateral septal nucleus, dorsal part
LSI lateral septal nucleus, intermediate part
LSV lateral septal nucleus, ventral part
LTz lateral nucleus of trapezoid body
LV lateral ventricle
Lve lateral vestibular nucleus
Mcd medial amygdaloid nucleus, dorsal part of central division
Mcv medial amygdaloid nucleus, ventral part of central division
MD mediodorsal thalamic nucleus
ME median eminence
Me5 mesencephalic trigeminal nucleus
MHb medial habenular nucleus
Mi mitral cell layer of olfactory bulb
Mo5 motor trigeminal nucleus
Mol molecular layer of cerebellum
MolDG molecular layer of dentate gyrus
mp medial parvocellular part, paraventricular hypothalamic nucleus
MS medial septal nucleus
MSO medial superior olive
MTz medial nucleus of trapezoid body
MVe medial vestibular nucleus
opt optic tract
Or oriens layer of hippocampus
PAC periamygdaloid nucleus
PCRt parvocellular reticular nucleus
PGi paragigantocellular reticular nucleus
Pir piriform cortex
pm posterior magnocellular part, paraventricular hypothalamic nucleus
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Pn pontine nuclei
PnC pontine reticular nucleus, caudal
PnO pontine reticular nucleus, oral
Pr5 principal sensory trigeminal nucleus
Pur Purkinje cell layer
PVN paraventricular hypothalamic nucleus
py pyramidal tract
Py pyramidal layer of hippocampus
PyTu pyramidal layer of olfactory bulb
Rad stratum radiatum of hippocampus
Rt reticular thalamic nucleus
scp superior cerebellar peduncle
sm stria medullaris thalamus
SNC substantia nigra pars compacta
SNR substantia nigra pars reticulate
SO supraoptic hypothalamic nucleus
sol solitary tract
SolL nucleus solitary tract, lateral part
SolM nucleus solitary tract, medial part
STh subthalamic nucleus
Su7 suprafacial nucleus
VCo ventral cochlear nucleus
VDBV nucleus of vertical limb of diagonal band, ventral part
VL ventrolateral thalamic nucleus
VLL ventral nucleus of lateral lemniscus
VM ventromedial thalamic nucleus
VMH ventromedial hypothalamic nucleus
VMHD
M
ventromedial hypothalamic nucleus, dorsomedial part
VMHV
L
ventromedial hypothalamic nucleus, ventrolateral part
VP ventral pallidum
VPB ventral parabrachial nucleus
VTg ventral tegmental nucleus
ZI zona incerta
Chen et al. Page 15
J Comp Neurol. Author manuscript; available in PMC 2011 June 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Acknowledgments
Grant sponsor: National Institutes of Health; Grant number: NS 28912; Grant sponsor: University of California
Systemwide Biotechnology Research and Education Program; Grant number: 98-02.
We thank Drs. O. Steward, A. Pitkänen, L. Seress, H. Yin, and R. Bender for their valuable comments on the
manuscript.
LITERATURE CITED
Aldenhoff JB, Gruol DL, Rivier J, Vale W, Siggins GR. Corticotropin releasing factor decreases
postburst hyperpolarizations and excites hippocampal neurons. Science. 1983; 221:875–877.
[PubMed: 6603658]
Avishai-Eliner S, Yi SJ, Baram TZ. Developmental profile of messenger RNA for the corticotropin-
releasing hormone receptor in the rat limbic system. Brain Res Dev Brain Res. 1996; 91:159–163.
Baram TZ, Hatalski CG. Neuropeptide-mediated excitability: a key triggering mechanism for seizure
generation in the developing brain. TINS. 1998; 21:471–476. [PubMed: 9829688]
Baram TZ, Ribak CE. Peptide-induced infant status epilepticus causes neuronal death and synaptic
reorganization. Neuroreport. 1995; 6:277–280. [PubMed: 7756609]
Baram TZ, Chalmers DT, Chen C, Koutsoukos Y, De Souza EB. The CRF1 receptor mediates the
excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo
evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res. 1997; 770:89–
95. [PubMed: 9372207]
Behan DP, Heinrichs SC, Troncoso JC, Liu XJ, Kawas CH, Ling N, De Souza EB. Displacement of
corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer’s
disease. Nature. 1995; 378:284–287. [PubMed: 7477348]
Castro MG, Morrison E, Perone MJ, Brown OA, Murray CA, Ahmed I, Perkins AV, Europe-Finner G,
Lowenstein PR, Linton EA. Corticotrophin-releasing hormone receptor type 1: generation and
characterization of polyclonal antipeptide antibodies and their localization in pituitary cells and
cortical neurones in vitro. J Neuroendocrinol. 1996; 8:521–531. [PubMed: 8843021]
Cha CI, Foote SL. Corticotropin-releasing factor in olivocerebellar climbing-fiber system of monkey
(Saimiri sciureus and Macaca fascicularis): parasagittal and regional organization visualized by
immunohistochemistry. J Neurosci. 1988; 8:4121–4137. [PubMed: 3263473]
Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor
receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with
CRF1 receptor mRNA expression. J Neurosci. 1995; 15:6340–6350. [PubMed: 7472399]
Chang CP, Pearse RVII, O’Connell S, Rosenfeld MG. Identification of a seven trans-membrane helix
receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron. 1993;
11:1187–1195. [PubMed: 8274282]
Chang D, Yi SJ, Baram TZ. Developmental profile of corticotropin releasing hormone messenger
RNA in the rat inferior olive. Int J Dev Neurosci. 1996; 14:69–76. [PubMed: 8779310]
Chen R, Lewis KA, Perrin MH, Vale WW. Expression cloning of a human corticotropin-releasing-
factor receptor. Proc Natl Acad Sci USA. 1993; 90:8967–8971. [PubMed: 7692441]
Chen YC, Chen QS, Lei JL, Wang SL. Physical training modifies the age-related decrease of GAP-43
and synaptophysin in the hippocampal formation in C57BL/6J mouse. Brain Res. 1998a; 806:238–
245. [PubMed: 9739145]
Chen YC, Lei JL, Chen QS, Wang SL. Effect of physical training on the age-related changes of
acetylcholinesterase-positive fibers in the hippocampal formation and parietal cortex in the
C57BL/6J mouse. Mech Ageing Dev. 1998b; 102:81–93. [PubMed: 9663794]
Conti LH, Foote SL. Effects of pretreatment with corticotropin-releasing factor on the
electrophysiological responsivity of the locus coeruleus to subsequent corticotropin-releasing
factor challenge. Neuroscience. 1995; 69:209–219. [PubMed: 8637619]
Cummings SL, Young WS III, King JS. Early development of cerebellar afferent systems that contain
corticotropin-releasing factor. J Comp Neurol. 1994; 350:534–549. [PubMed: 7890829]
Chen et al. Page 16
J Comp Neurol. Author manuscript; available in PMC 2011 June 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
De Souza EB. Corticotropin-releasing factor receptors in the rat central nervous system:
characterization and regional distribution. J Neurosci. 1987; 7:88–100. [PubMed: 3027279]
De Souza EB, Kuhar MJ. Corticotropin-releasing factor receptors in the pituitary gland and central
nervous system: methods and overview. Methods Enzymol. 1986; 124:560–590. [PubMed:
3012254]
De Souza EB, Insel TR, Perrin MH, Rivier J, Vale WW, Kuhar MJ. Corticotropin-releasing factor
receptors are widely distributed within the rat central nervous system: an autoradiographic study. J
Neurosci. 1985; 5:3189–3203. [PubMed: 3001239]
Dolorfo CL, Amaral DG. Entorhinal cortex of the rat: organization of intrinsic connections. J Comp
Neurol. 1998; 398:49–82. [PubMed: 9703027]
Eghbal-Ahmadi M, Hatalski CG, Lovenberg TW, Avishai-Eliner S, Chalmers DT, Baram TZ. The
developmental profile of the corticotropin releasing factor receptor (CRF2) in rat brain predicts
distinct age-specific functions. Brain Res Dev Brain Res. 1998; 107:81–90.
Eghbal-Ahmadi M, Avishai-Eliner S, Hatalski CG, Baram TZ. Differential regulation of the
expression of corticotropin-releasing factor receptor type 2 (CRF2) in hypothalamus and amygdala
of the immature rat by sensory input and food intake. J Neurosci. 1999; 19:3982–3991. [PubMed:
10234028]
Ehlers CL, Henriksen SJ, Wang M, Rivier J, Vale W, Bloom FE. Corticotropin releasing factor
produces increases in brain excitability and convulsive seizures in rats. Brain Res. 1983; 278:332–
336. [PubMed: 6605787]
Gray TS, Bingaman EW. The amygdala: corticotropin-releasing factor, steroids, and stress. Crit Rev
Neurobiol. 1996; 10:155–168. [PubMed: 8971127]
Grigoriadis DE, Lovenberg TW, Chalmers DT, Liaw C, De Souza EB. Characterization of
corticotropin-releasing factor receptor subtypes. Ann NY Acad Sci. 1996; 780:60–80. [PubMed:
8602740]
Hatalski CG, Guirguis C, Baram TZ. Corticotropin releasing factor mRNA expression in the
hypothalamic paraventricular nucleus and the central nucleus of the amygdala is modulated by
repeated acute stress in the immature rat. J Neuroendocrinol. 1998; 10:663–669. [PubMed:
9744483]
Hollrigel GS, Chen K, Baram TZ, Soltesz I. The pro-convulsant actions of corticotropin-releasing
hormone in the hippocampus of infant rats. Neuroscience. 1998; 84:71–79. [PubMed: 9522363]
Imaki J, Imaki T, Vale W, Sawchenko PE. Distribution of corticotropin-releasing factor mRNA and
immunoreactivity in the central auditory system of the rat. Brain Res. 1991; 547:28–36. [PubMed:
1713530]
Imaki T, Naruse M, Harada S, Chikada N, Imaki J, Onodera H, Demura H, Vale W. Corticotropin-
releasing factor up-regulates its own receptor mRNA in the paraventricular nucleus of the
hypothalamus. Brain Res Mol Brain Res. 1996; 38:166–170. [PubMed: 8737681]
Kawata M, Hashimoto K, Takahara J, Sano Y. Immunohistochemical identification of neurons
containing corticotropin-releasing factor in the rat hypothalamus. Cell Tissue Res. 1983; 230:239–
246. [PubMed: 6342798]
King JS, Madtes P Jr, Bishop GA, Overbeck TL. The distribution of corticotropin-releasing factor
(CRF), CRF binding sites and CRF1 receptor mRNA in the mouse cerebellum. Prog Brain Res.
1997; 114:55–66. [PubMed: 9193138]
Kostich WA, Chen A, Sperle K, Largent BL. Molecular identification and analysis of a novel human
corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol. 1998;
12:1077–1085. [PubMed: 9717834]
Lee EH, Lee CP, Wang HI, Lin WR. Hippocampal CRF, NE, and NMDA system interactions in
memory processing in the rat. Synapse. 1993; 14:144–153. [PubMed: 7687386]
Lehnert H, Schulz C, Dieterich K. Physiological and neurochemical aspects of corticotropin-releasing
factor actions in the brain: the role of the locus coeruleus. Neurochem Res. 1998; 23:1039–1052.
[PubMed: 9704593]
Liang KC, Lee EH. Intra-amygdala injections of corticotropin releasing factor facilitate inhibitory
avoidance learning and reduce exploratory behavior in rats. Psychopharmacology. 1988; 96:232–
236. [PubMed: 3148150]
Chen et al. Page 17
J Comp Neurol. Author manuscript; available in PMC 2011 June 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, Oltersdorf T.
Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor
subtype from rat brain. Proc Natl Acad Sci USA. 1995; 92:836–840. [PubMed: 7846062]
Luo X, Kiss A, Makara G, Lolait SJ, Aguilera G. Stress-specific regulation of corticotropin releasing
hormone receptor expression in the paraventricular and supraoptic nuclei of the hypothalamus in
the rat. J Neuroendocrinol. 1994; 6:689–696. [PubMed: 7894472]
Moga MM, Saper CB, Gray TS. Bed nucleus of the stria terminalis: cyto-architecture,
immunohistochemistry, and projection to the parabrachial nucleus in the rat. J Comp Neurol. 1989;
283:315–332. [PubMed: 2568370]
Muglia L, Jacobson L, Dikkes P, Majzoub JA. Corticotropin-releasing hormone deficiency reveals
major fetal but not adult glucocorticoid need. Nature. 1995; 373:427–432. [PubMed: 7830793]
Owens MJ, Nemeroff CB. The role of corticotropin-releasing factor in the pathophysiology of
affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp. 1993; 172:296–
308. [PubMed: 8491091]
Palchaudhuri MR, Wille S, Mevenkamp G, Spiess J, Fuchs E, Dautzenberg FM. Corticotropin-
releasing factor receptor type 1 from Tupaia belangeri—cloning, functional expression and tissue
distribution. Eur J Biochem. 1998; 258:78–84. [PubMed: 9851694]
Paxinos, G.; Watson, C. The rat brain in stereotaxic coordinates. New York: Academic Press; 1982.
Perrin MH, Donaldson CJ, Chen R, Lewis KA, Vale WW. Cloning and functional expression of a rat
brain corticotropin releasing factor (CRF) receptor. Endocrinology. 1993; 133:3058–3061.
[PubMed: 8243338]
Pitkänen A, Savander V, LeDoux JE. Organization of intra-amygdaloid circuitries in the rat: an
emerging framework for understanding functions of the amygdala. TINS. 1997; 20:517–523.
[PubMed: 9364666]
Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K, Sawchenko PE, Vale W. Distribution of
corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl
Acad Sci USA. 1994; 91:8777–8781. [PubMed: 8090722]
Powers RE, DeSouza EB, Walker LC, Price DL, Vale WW, Young WS. Corticotropin-releasing factor
as a transmitter in the human olivocerebellar pathway. Brain Res. 1987; 415:347–352. [PubMed:
2886191]
Radulovic J, Sydow S, Spiess J. Characterization of native corticotropin-releasing factor receptor type
1 in the rat and mouse central nervous system. J Neurosci Res. 1998; 54:507–521. [PubMed:
9822161]
Ribak CE, Baram TZ. Selective death of hippocampal CA3 pyramidal cells with mossy fiber afferents
after CRH-induced status epilepticus in infant rats. Brain Res Dev Brain Res. 1996; 91:245–251.
Rivest S, Laflamme N, Nappi RE. Immune challenge and immobilization stress induce transcription of
the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. J Neurosci. 1995;
15:2680–2695. [PubMed: 7722622]
Sakanaka M, Shibasaki T, Lederis K. Distribution and efferent projections of corticotropin-releasing
factor-like immunoreactivity in the rat amygdaloid complex. Brain Res. 1986; 382:213–238.
[PubMed: 2428439]
Sakanaka M, Shibasaki T, Lederis K. Corticotropin releasing factorlike immunoreactivity in the rat
brain as revealed by a modified cobalt-glucose oxidase-diaminobenzidine method. J Comp Neurol.
1987; 260:256–298. [PubMed: 3497182]
Sanchez MM, Young LJ, Plotsky PM, Insel TR. Autoradiographic and in situ hybridization
localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp
Neurol. 1999; 408:365–377. [PubMed: 10340512]
Sawchenko PE. Evidence for differential regulation of corticotropin-releasing factor and vasopressin
immunoreactivities in parvocellular neurosecretory and autonomic-related projections of the
paraventricular nucleus. Brain Res. 1987; 437:253–263. [PubMed: 3325130]
Sawchenko PE, Swanson LW. Localization, colocalization, and plasticity of corticotropin-releasing
factor immunoreactivity in rat brain. Fed Proc. 1985; 44:221–227. [PubMed: 2981743]
Chen et al. Page 18
J Comp Neurol. Author manuscript; available in PMC 2011 June 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Sawchenko, PE.; Swanson, LW. Organization of CRF immunoreactive cells and fibers in the rat brain:
immunohistochemical studies. In: De Souza, EB.; Nemeroff, CB., editors. Corticotropin-releasing
factor: basic and clinical studies of a neuropeptide. Boca Raton, FL: CRC Press; 1990. p. 29-46.
Sawchenko PE, Imaki T, Potter E, Kovacs K, Imaki J, Vale W. The functional neuroanatomy of
corticotropin-releasing factor. Ciba Found Symp. 1993; 172:5–21. [PubMed: 8491094]
Sawchenko PE, Brown ER, Chan RK, Ericsson A, Li HY, Roland BL, Kovacs KJ. The paraventricular
nucleus of the hypothalamus and the functional neuroanatomy of visceromotor responses to stress.
Prog Brain Res. 1996; 107:201–222. [PubMed: 8782521]
Sidman, RL.; Angevine, JB.; Pierce, ET. Atlas of the mouse brain and spinal cord. Cambridge, MA:
Harvard University Press; 1971.
Siggins GR, Gruol D, Aldenhoff J, Pittman Q. Electrophysiological actions of corticotropin-releasing
factor in the central nervous system. Fed Proc. 1985; 44:237–242. [PubMed: 3155696]
Smith BN, Dudek FE. Age-related epileptogenic effects of corticotropin-releasing hormone in the
isolated CA1 region of rat hippocampal slices. J Neurophysiol. 1994; 72:2328–2333. [PubMed:
7884462]
Swanson LW, Kuypers HG. The paraventricular nucleus of the hypothalamus: cyto-architectonic
subdivisions and organization of projections to the pituitary, dorsal vagal complex, and spinal cord
as demonstrated by retrograde fluorescence double-labeling methods. J Comp Neurol. 1980;
194:555–570. [PubMed: 7451682]
Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corticotropin-releasing factor
immunoreactive cells and fibers in the rat brain: an immunohistochemical study.
Neuroendocrinology. 1983; 36:165–186. [PubMed: 6601247]
Swanson LW, Sawchenko PE, Lind RW. Regulation of multiple peptides in CRF parvo-cellular
neurosecretory neurons: implications for the stress response. Prog Brain Res. 1986; 68:169–190.
[PubMed: 3550889]
Swanson LW, Sawchenko PE, Lind RW, Rho JH. The CRH motoneuron: differential peptide
regulation in neurons with possible synaptic, paracrine, and endocrine outputs. Ann NY Acad Sci.
1987; 512:12–23. [PubMed: 3327422]
Uryu K, Okumura T, Shibasaki T, Sakanaka M. Fine structure and possible origins of nerve fibers with
corticotropin-releasing factorlike immunoreactivity in the rat central amygdaloid nucleus. Brain
Res. 1992; 577:175–179. [PubMed: 1521144]
Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that
stimulates secretion of corticotropin and beta-endorphin. Science. 1981; 213:1394–1397.
[PubMed: 6267699]
Valentino RJ, Wehby RG. Corticotropin-releasing factor: evidence for a neurotransmitter role in the
locus ceruleus during hemodynamic stress. Neuroendocrinology. 1988; 48:674–677. [PubMed:
2908000]
Valentino RJ, Page M, Van Bockstaele E, Aston-Jones G. Corticotropin-releasing factor innervation of
the locus coeruleus region: distribution of fibers and sources of input. Neuroscience. 1992;
48:689–705. [PubMed: 1376457]
Veening JG, Swanson LW, Sawchenko PE. The organization of projections from the central nucleus of
the amygdala to brainstem sites involved in central autonomic regulation: a combined retrograde
transport-immunohistochemical study. Brain Res. 1984; 303:337–357. [PubMed: 6204716]
Vita N, Laurent P, Lefort S, Chalon P, Lelias JM, Kaghad M, Le Fur G, Caput D, Ferrara P. Primary
structure and functional expression of mouse pituitary and human brain corticotrophin releasing
factor receptors. FEBS Lett. 1993; 335:1–5. [PubMed: 8243652]
Weninger SC, Muglia LJ, Jacobson L, Majzoub JA. CRH-deficient mice have a normal anorectic
response to chronic stress. Regul Pept. 1999; 84:69–74. [PubMed: 10535410]
Yan XX, Baram TZ, Gerth A, Schultz L, Ribak CE. Co-localization of corticotropin-releasing
hormone with glutamate decarboxylase and calcium-binding proteins in infant rat neocortical
interneurons. Exp Brain Res. 1998a; 123:334–340. [PubMed: 9860272]
Yan XX, Toth Z, Schultz L, Ribak CE, Baram TZ. Corticotropin-releasing hormone (CRH)-containing
neurons in the immature rat hippocampal formation: light and electron microscopic features and
Chen et al. Page 19
J Comp Neurol. Author manuscript; available in PMC 2011 June 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
colocalization with glutamate decarboxylase and parvalbumin. Hippocampus. 1998b; 8:231–243.
[PubMed: 9662138]
Young WS III, Walker LC, Powers RE, De Souza EB, Price DL. Corticotropin-releasing factor mRNA
is expressed in the inferior olives of rodents and primates. Brain Res. 1986; 387:189–192.
[PubMed: 3539260]
Chen et al. Page 20
J Comp Neurol. Author manuscript; available in PMC 2011 June 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1.
The anti-CRF1 antiserum recognizes a single protein species, as evident from Western blot
analysis. Cell lysates were prepared from mouse hypothalamus (lanes 1 and 3) and
cerebellum (lanes 2 and 4). Aliquots of 50 µg protein were loaded in each lane. Following
inclubation (see Materials and Methods), a single band of approximately 80 kDa was
recognized by CRF1 antiserum (1:500). Lanes 3 and 4 show that preadsorption of CRF1
antiserum with the antigenic peptide leads to disappearance of this band.
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Fig. 2.
Illustration of the three principal patterns of neuronal CRF1-like immunoreactivity (CRF1-
LI) in mouse brain. CRF1-LI is characterized as granular (A, cerebellar Purkinje cells),
punctate (B, parafascicular thalamic nucleus), or homogenous (arrows in C, lateral
hypothalamic area). D: Preadsorption of the antiserum with the immunogenic epitope
eliminates all the reaction signal (section shown is from thalamus). Scale bar = 40 µm
(applies to A–D).
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Fig. 3.
Distribution of CRF1-like immunoreactivity in the olfactory and cortical regions: (A)
olfactory bulb, (B) olfactory tubercle, (C) neocortex, (D) piriform cortex, and (E) entorhinal
cortex. Enlargement in C shows the strongly labeled pyramidal neurons in layer V. Cortical
layers are denoted by Roman numerals. Scale bars = 80 µm in E (applies to A–E); 20 µm in
inset in C.
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Fig. 4.
Distribution of CRF1-like immunoreactivity in the hippocampal formation (A). B:
Morphology of CRF1-LI-expressing neurons in hippocampal CA2–3a area. C,D: CRF1-like
immunoreactivity in the dentate gyrus and subiculum, respectively. Within the dentate
gyrus, granular cell somata are outlined by a fine mesh of weakly stained puncta, and
intensely labeled neurons are present in the hilus. Most pyramidal neurons are intensely
labeled in the subiculum. Scale bars = 200 µm in A; 80 µm in D (applies to B–D).
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Fig. 5.
Distribution of CRF1-like immunoreactivity in the amygdala (A) and the morphology of
neurons showing CRF1-LI in basal (B), medial (C), and central (D) nuclei. These neurons
are intensely labeled throughout the magnocellular division of basal nucleus (Bmc). Within
the medial nucleus (Mcd and Mcv), CRF1 immunoreaction product frequently outlines only
a portion of the cell surface. In the central nucleus, the lateral (CEl) and medial (CEm)
divisions show a different staining pattern: whereas immunoreactivity in CEl consists of
punctate deposits, the CEm consists of an outline of only a portion of the cell surface. Scale
bars = 200 µm in A; 40 µm in D (applies to B–D).
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Fig. 6.
Distribution of neurons showing CRF1-LI in septum (A). Higher magnification, illustrating
characteristic CRF1-ir neurons in dorsal (B) and lateral (C) septal nuclei, and in the vertical
limb of the nucleus of the diagonal band of Broca (D). E,F: CRF1-like immunoreactivity in
the basal ganglia, including the accumbens nucleus (Acb) and ventral striatum (VP). Scale
bars = 200 µm in A; 40 µm in C (applies to B,C); 80 µm in F (applies to D–F).
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Fig. 7.
Distribution of neurons labeled for CRF1-LI in thalamus (A). B: Higher magnification
showing CRF1-ir neurons in the nucleus reticularis. C: CRF1-like immunoreactivity in the
subthalamus (STh) and zona incerta (ZI). Scale bars = 40 µm in B; 80 µm in C (applies to
A,C)
Chen et al. Page 27
J Comp Neurol. Author manuscript; available in PMC 2011 June 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 8.
A series of coronal sections from rostral to caudal of the paraventricular nucleus, showing
neurons intensely labeled for CRF1-LI (A–C). Similar neurons in the supraoptic nucleus
(D), arcuate nucleus and median eminence (E), and ventromedial nucleus (F). Scale bar = 80
µm (applies to A–F).
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Fig. 9.
Distribution of CRF1-like immunoreactivity in the superior (A) and inferior (B) colliculus. A
few deeply labeled neurons are present in the lateral part of layer VI. In the inferior
colliculus, strongly stained neurons are scattered in both the cortical and central nuclei,
where most medium-sized neurons are moderately labeled. CRF1-LI-expressing neurons in
the ventral tegmental nuclei (C), red nucleus (D), and substantia nigra (E) are strongly
labeled. The accessory oculomotor nucleus (Edinger-Westphal, F) is moderately or intensely
labeled, whereas the dorsal raphe nucleus (G) is rich in highly labeled neurons. Scale bar =
80 µm (applies to A–G).
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Fig. 10.
Neurons showing CRF1-like immunoreactivity in nuclei of the trigeminal nerve (A), facial
nucleus (B), vestibular nuclei (C), vagal dorsal motor nucleus and hypoglossal nucleus (D),
ambiguous nucleus (E), and solitary tract nucleus (F). Scale bars = 160 µm in B,C; 80 µm in
F (applies to A,D–F).
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Fig. 11.
CRF1-like immunoreactive neurons in locus coeruleus (A) and parabrachial nuclei (B). C–
E: Distribution of labeled neurons in cochlear nuclei (C), trapezoid body (D), and ventral
nucleus of lateral lemniscus (E). F,G: Immunoreactive neurons in the inferior olive and
cerebellum, respectively. Within the cerebellum, Purkinje cells are intensely labeled. The
granular layer contains scattered intensely labeled neurons, as well as numerous weakly
stained fine puncta. Scale bars = 200 µm in F (applies to C–F);80 µm in G (applies to
A,B,G).
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TABLE 1
Distribution of Neurons Expressing CRF1-LI in the Mouse Telencephalon: Density and Intensity
Region Density1 Intensity2
Olfactory bulb
   Glomerular layer ++ ++/
+++3
   External plexiform layer + +
   Mitral cell layer ++++ ++
   Internal plexiform layer ++ ++
   Granular cell layer ++++ +/++
Accessory olfactory bulb
   Mitral cell layer ++++ ++
   Granular cell layer ++++ +/++
Olfactory tubercle
   Polymorphic layer +++ +/++
   Pyramidal layer ++++ +/++
Island of Calleja +++ +/++
Taenia tecta ++++ ++
Claustrum ++++ +/++
Endopiriform nucleus +++ ++
Neocortex
   Layer I + +
   Layer II ++++ ++
   Layer III ++++ ++
   Layer IV ++++ +
   Layer V ++++ ++++
   Layer VI ++++ +/++
Piriform cortex
   Layer I + ++
   Layer II ++++ ++/+++
   Layer III ++++ ++/+++
Entorhinal cortex
   Layer IIa ++++ ++/+++
   Layer IIb +++ ++
   Layer III ++++ ++
   Layers V–VI +++ ++/+++
Perirhinal cortex ++++ ++
Hippocampal formation
   Hippocampus
      CA1 pyramidal layer ++++ ++
      CA3a pyramidal layer ++++ +++
      CA3b,c pyramidal layer ++++ +/++
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Region Density1 Intensity2
   Dentate gyrus
      Hilus ++ +++
      Granular layer ++++ +
      Molecular layer −/+ ++
   Subiculum +++ +++/
++++
Amygdala
   Medial nucleus ++++ ++
   Cortical nucleus ++++ +/++
   Central nucleus
      Medial +++ +/++
      Lateral ++++ +/++
   Basal nucleus +++ ++++
   Lateral nucleus +++ +
Bed nucleus of stria
   terminalis
   Medical part +++ ++
   Lateral part ++++ ++
Basal ganglia
   Caudate-putamen ++++ +
   Nucleus accumbens ++++ +/++
   Fundus striati +++ ++
   Globus pallidus ++ ++/+++
   Ventral pallidus ++ +++
   Entopeduncular nucleus ++ +++
Septum
   Lateral septal nucleus ++++ +++
   Medical septal nucleus ++++ ++/+++
Diagonal band of Broca
   Vertical limb +++ +++
   Horizontal limb +++ +++
1
Density values are based on the percentage of positive cells related to total cell number. −, no positive cells; −/+, occasional cells, <10%; +, low,
10–25%; ++, moderate, 25–50%; +++, dense, 50–75%; ++++, very dense, >75%.
2
Staining intensity: +, weakly positive; ++, moderately positive; +++, intensely positive; ++++, strongly intense.
3
Two scores are noted because the region contains cell populations with different labeling intensity.
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TABLE 2
Distribution of Neurons Expressing CRF1-LI in the Mouse Diencephalon: Density and Intensity
Region Density1 Intensity2
Habenula
   Medial part ++++ +++
   Lateral part ++ ++
Thalamus
   Anterodorsal nucleus ++ +++/++++3
   Antroventral nucleus +++ ++
   Anteromedial nucleus +++ +++
   Mediodorsal nucleus +++ +++
   Lateral dorsal nucleus ++ +++
   Lateral postrior nucleus ++ +++
   Ventral lateral nucleus ++ +++
   Ventral postrolateral nucleus ++ +++
   Ventral postromedial nucleus ++ +++
   Paraventricular nucleus +++ +++/++++
   Midline nuclear group ++ ++/+++
   Intralaminar nuclear group ++ ++/+++
   Thalamic reticular nucleus ++ +/++
Hypothalamus
   Medial preoptic area +++ +++
   Lateral preoptic area +++ ++
   Suprachiasmatic nucleus +++ ++
   Retrochiasmatic nucleus ++ +
   Supraoptic nucleus ++++ ++++
   Paraventricular nucleus
      Medial parvocellular division +++ +++/++++
      Magnocellular division + +
   Ventromedial nucleus ++++ ++/+++
   Arcuate nucleus ++++ +++/++++
   Anterior hypothalamic area +++ ++
   Lateral hypothalamic area +++ +/++
   Dorsal hypothalamic area +++ +
   Dorsomedial nucleus +++ +
   Median eminence + +++
Subthalamic nucleus ++++ ++/+++
Zona incerta +++ +/++
Medial geniculate body +++ +++
Lateral geniculate body +++ ++/+++
1
Density values are based on the percentage of positive cells related to total cell number. −, no positive cells; −/+, occasional cells, <10%; +, low,
10–25%; ++, moderate, 25–50%; +++, dense, 50–75%; ++++, very dense, >75%.
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2
Staining intensity; +, weakly positive; ++, moderately positive; +++, intensely positive; ++++, strongly intense.
3
Two scores are noted because the region contains cell populations with different labeling intensity.
J Comp Neurol. Author manuscript; available in PMC 2011 June 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Chen et al. Page 36
TABLE 3
Distribution of Neurons Expressing CRF1-LI in the Mouse Hindbrain: Density and Intensity
Region Density1 Intensity2
Superior colliculus ++ +/++3
Inferior colliculus ++ +/++
Tegmental nuclei +++ ++/+++
Pedunculopontine nucleus +++ +++
Red nucleus ++++4 +++
Substantia nigra
   Pars compacta ++ +++
   Pars reticulata ++ ++/+++
Raphe nuclei
   Dorsal nucleus ++ +++/++++
   Median nucleus + ++
Edinger-Westphal nucleus +++ +/++
Principal oculomotor
   nucleus
+++ +++
Darkschewitsch nucleus
Nuclei of the trigeminal
   nerve
   Mesencephalic nucleus ++++ +++
   Motor nucleus ++++4 +++
   Principal sensory
   nucleus
+++ +/++
   Spinal nucleus ++ +/++
Facial nucleus ++++4 +++
Vestibular nuclei +++ ++/+++
Cochlear nuclei
   Dorsal nucleus ++ ++
   Ventral nucleus ++ +++
Vagus nucleus ++++ ++++
Hypoglossal nucleus ++++ +++
Solitary nucleus +++ +/++
Ambiguus nucleus +++ ++++
Locus coeruleus +++ ++++
Superior olive +++ +++
Inferior olive +++ ++/+++
Nuclei of lateral
   lemniscus
+++ +++
Nucleus of trapezoid body
   Medial nucleus ++++ ++++
   Lateral nucleus +++ ++
Cerebellum
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Region Density1 Intensity2
   Molecular layer +++ +
   Purkinje cell layer ++++ ++++
   Granular cell layer +++ +
   Cerebellar nuclei +++ +++
1
Density values are based on the percentage of positive cells related to total cell number. −, no positive cells; −/+, occasional cells, <10%; +, low,
10–5%; ++, moderate, 25–50%; +++, dense, 50–75%; ++++, very dense, >75%.
2
Staining intensity: +, weakly positive; ++, moderately positive; +++, intensely positive; ++++, strongly intense.
3
Two scores are noted because the region contains cell populations with different labeling intensity.
4
All large, multipolar neurons were CRF1 immunoreactive.
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